304 related articles for article (PubMed ID: 15734724)
21. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Smith SA; Lister CA; Toseland CD; Buckingham RE
Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
[TBL] [Abstract][Full Text] [Related]
23. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
24. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
25. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
[TBL] [Abstract][Full Text] [Related]
26. The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels.
Liem DA; Gho CC; Gho BC; Kazim S; Manintveld OC; Verdouw PD; Duncker DJ
J Pharmacol Exp Ther; 2004 Jun; 309(3):1256-62. PubMed ID: 14993257
[TBL] [Abstract][Full Text] [Related]
27. Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.
Yuen VG; Bhanot S; Battell ML; Orvig C; McNeill JH
Can J Physiol Pharmacol; 2003 Nov; 81(11):1049-55. PubMed ID: 14719040
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Cai XJ; Lister CA; Buckingham RE; Pickavance L; Wilding J; Arch JR; Wilson S; Williams G
Brain Res Mol Brain Res; 2000 Apr; 77(1):131-7. PubMed ID: 10814839
[TBL] [Abstract][Full Text] [Related]
29. Cocoa-rich diet ameliorates hepatic insulin resistance by modulating insulin signaling and glucose homeostasis in Zucker diabetic fatty rats.
Cordero-Herrera I; Martín MÁ; Escrivá F; Álvarez C; Goya L; Ramos S
J Nutr Biochem; 2015 Jul; 26(7):704-12. PubMed ID: 25814291
[TBL] [Abstract][Full Text] [Related]
30. Bis(maltolato)oxovanadium(IV) (BMOV) Attenuates Apoptosis in High Glucose-Treated Cardiac Cells and Diabetic Rat Hearts by Regulating the Unfolded Protein Responses (UPRs).
Cong XQ; Piao MH; Li Y; Xie L; Liu Y
Biol Trace Elem Res; 2016 Oct; 173(2):390-8. PubMed ID: 26983714
[TBL] [Abstract][Full Text] [Related]
31. Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide.
Alemzadeh R; Tushaus KM
Endocrinology; 2004 Dec; 145(12):5476-84. PubMed ID: 15319354
[TBL] [Abstract][Full Text] [Related]
32. [Hypoglycemic effects of bis(maltolato)oxovanadium administered by different routes upon diabetic rats].
Zhong XY; Zhang H; Zhang X; Lv WL; Zhang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 36(3):313-8. PubMed ID: 15205708
[TBL] [Abstract][Full Text] [Related]
33. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
[TBL] [Abstract][Full Text] [Related]
34. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends.
Ścibior A; Pietrzyk Ł; Plewa Z; Skiba A
J Trace Elem Med Biol; 2020 Sep; 61():126508. PubMed ID: 32305626
[TBL] [Abstract][Full Text] [Related]
35. Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes.
Dabroś W; Kordowiak AM; Dziga D; Gryboś R
Pol J Pathol; 1998; 49(2):67-76. PubMed ID: 9798409
[TBL] [Abstract][Full Text] [Related]
36. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats.
Li SH; McNeill JH
Mol Cell Biochem; 2001 Jan; 217(1-2):121-9. PubMed ID: 11269655
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
Li M; Ding W; Baruah B; Crans DC; Wang R
J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction.
Shah DI; Singh M
Vascul Pharmacol; 2006 Mar; 44(3):177-82. PubMed ID: 16442349
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
40. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
Wu Y; Ouyang JP; Wu K; Wang SS; Wen CY; Xia ZY
Br J Pharmacol; 2005 Sep; 146(2):234-43. PubMed ID: 15997237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
